Concurrent Investment Advisors LLC Invests $1.12 Million in CRISPR Therapeutics AG $CRSP

Concurrent Investment Advisors LLC purchased a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) in the second quarter, HoldingsChannel reports. The fund purchased 22,967 shares of the company’s stock, valued at approximately $1,117,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. IFP Advisors Inc grew its holdings in shares of CRISPR Therapeutics by 24.6% during the second quarter. IFP Advisors Inc now owns 916 shares of the company’s stock worth $45,000 after buying an additional 181 shares in the last quarter. McElhenny Sheffield Capital Management LLC purchased a new stake in shares of CRISPR Therapeutics during the second quarter worth about $6,615,000. Slow Capital Inc. grew its holdings in shares of CRISPR Therapeutics by 15.6% during the second quarter. Slow Capital Inc. now owns 75,396 shares of the company’s stock worth $3,667,000 after buying an additional 10,152 shares in the last quarter. KLP Kapitalforvaltning AS grew its holdings in shares of CRISPR Therapeutics by 6.8% during the second quarter. KLP Kapitalforvaltning AS now owns 17,200 shares of the company’s stock worth $837,000 after buying an additional 1,100 shares in the last quarter. Finally, Tyche Wealth Partners LLC grew its holdings in shares of CRISPR Therapeutics by 71.9% during the second quarter. Tyche Wealth Partners LLC now owns 15,785 shares of the company’s stock worth $768,000 after buying an additional 6,600 shares in the last quarter. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CEO Samarth Kulkarni sold 4,242 shares of the business’s stock in a transaction on Tuesday, October 14th. The shares were sold at an average price of $66.60, for a total transaction of $282,517.20. Following the transaction, the chief executive officer directly owned 205,096 shares of the company’s stock, valued at approximately $13,659,393.60. The trade was a 2.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, General Counsel James R. Kasinger sold 1,076 shares of the business’s stock in a transaction on Tuesday, October 14th. The stock was sold at an average price of $66.60, for a total transaction of $71,661.60. Following the transaction, the general counsel directly owned 83,402 shares in the company, valued at approximately $5,554,573.20. The trade was a 1.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 4.30% of the company’s stock.

CRISPR Therapeutics Stock Up 3.5%

Shares of CRSP stock opened at $71.82 on Thursday. The stock has a market cap of $6.53 billion, a price-to-earnings ratio of -13.23 and a beta of 1.84. CRISPR Therapeutics AG has a fifty-two week low of $30.04 and a fifty-two week high of $78.48. The firm’s 50 day moving average price is $59.90 and its two-hundred day moving average price is $49.51.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Monday, August 4th. The company reported ($1.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.18. The firm had revenue of $0.89 million for the quarter, compared to analysts’ expectations of $6.44 million. CRISPR Therapeutics had a negative net margin of 1,229.43% and a negative return on equity of 20.05%. CRISPR Therapeutics’s revenue was up 72.5% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.49) earnings per share. On average, equities analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on CRSP shares. Needham & Company LLC reissued a “buy” rating and issued a $81.00 target price on shares of CRISPR Therapeutics in a research report on Friday, October 10th. Royal Bank Of Canada raised their target price on shares of CRISPR Therapeutics from $38.00 to $42.00 and gave the stock a “sector perform” rating in a research report on Tuesday, August 5th. Barclays raised their target price on shares of CRISPR Therapeutics from $42.00 to $56.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 6th. JMP Securities reissued a “market outperform” rating and issued a $86.00 target price on shares of CRISPR Therapeutics in a research report on Friday, June 27th. Finally, Wells Fargo & Company set a $75.00 target price on shares of CRISPR Therapeutics in a research report on Monday. Ten investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $71.71.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.